Dark

Check out our Level2View

ARFXF
PROMIS NEUROSCIENCES INC
stock OTC

Inactive

Jun 27, 2022

0.1020USD-0.585%(-0.0006)685,017

Pre-market

0.00USD-100.000%(-0.10)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 27, 2022

07:00AM EST ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, announced today that it has appointed Dr. Cheryl Wellington to its scientific advisory board (SAB). GlobeNewswire Inc

Jan 18, 2022

07:00AM EST ProMIS Neurosciences Announces Antibody Program for Schizophrenia GlobeNewswire Inc

Jan 7, 2022

07:00AM EST ProMIS Neurosciences to Participate in the Biotech Showcase 2022 GlobeNewswire Inc

Jan 6, 2022

07:30AM EST ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, announced today its participation in theH.C. Wainwright BioConnect 2022 Virtual Conferencebeing held January 1013, 2022. GlobeNewswire Inc

Dec 16, 2021

07:30AM EST ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, issued today a Chairmans Memorandum commenting on the Companys progress over the past year and outlook for 2022. GlobeNewswire Inc

Dec 2, 2021

07:00AM EST ProMIS Neurosciences Shareholders Approve Special Resolution GlobeNewswire Inc

Nov 17, 2021

07:00AM EST For any questions, please contact ProMIS proxy solicitation agent, Laurel Hill Advisory Group at 1-877- 452-7184 (+1-416-304-0211 outside North America) or email assistance@laurelhill.com. GlobeNewswire Inc

Nov 12, 2021

07:00AM EST ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (ProMIS or the Company), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced its operational and financial results for the three and nine months ended September 30, 2021. GlobeNewswire Inc

Nov 2, 2021

07:00AM EDT For any questions, please contact ProMIS proxy solicitation agent, Laurel Hill Advisory Group at 1-877- 452-7184 (+1-416-304-0211 outside North America) or email assistance@laurelhill.com. GlobeNewswire Inc

Oct 22, 2021

07:00AM EDT ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics selectively targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced several updates to its senior management team. GlobeNewswire Inc

07:00AM EDT ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics selectively targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced the appointment of Maggie Shafmaster, PhD, JD, to its Board of Directors with immediate effect. GlobeNewswire Inc

Oct 21, 2021

07:00AM EDT For any questions, please contact ProMIS proxy solicitation agent, Laurel Hill Advisory Group at 1-877-452-7184 (+1-416-304-0211 outside North America) or email assistance@laurelhill.com. GlobeNewswire Inc

Oct 7, 2021

07:00AM EDT ProMIS Neurosciences Announces Special Shareholder Meeting GlobeNewswire Inc

Sep 15, 2021

07:30AM EDT ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, announced today its participation in the Second Annual Undruggable Leaders Forum, a virtual event to be held on September 15-16. GlobeNewswire Inc

Sep 13, 2021

07:30AM EDT ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, announced today its participation in H.C. Wainwright & Co., 23rd Annual Investment Conference being held virtually September 13-15 2021. GlobeNewswire Inc

Sep 1, 2021

07:30AM EDT ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics selectively targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced the appointment of Josh Mandel-Brehm to its Board of Directors with immediate effect. GlobeNewswire Inc

Aug 12, 2021

07:30AM EDT ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (ProMIS or the Company), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced its operational and financial results for the three and six months ended June 30, 2021. GlobeNewswire Inc

Aug 4, 2021

07:30AM EDT ProMIS Neurosciences Issues Chairmans Memorandum GlobeNewswire Inc

Jul 22, 2021

07:15AM EDT ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, will give two presentations at the annual Alzheimers Association International Conference (AAIC) to be held July 26-30, 2021 in Denver, USA and online. GlobeNewswire Inc

Jul 2, 2021

07:30AM EDT ProMIS Neurosciences Announces Results of Annual Meeting of GlobeNewswire Inc

Jun 8, 2021

07:30AM EDT ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today congratulates Biogen on the recent FDA approval of its monoclonal antibody therapeutic, aducanumab, for the treatment of Alzheimers disease (AD). GlobeNewswire Inc

May 27, 2021

07:30AM EDT ProMIS Neurosciences appoints renowned scientist, Dr. David GlobeNewswire Inc

May 25, 2021

07:30AM EDT ProMIS Neurosciences initiates commercialization of COVID-19 GlobeNewswire Inc

May 21, 2021

08:30AM EDT ProMIS Neurosciences re-initiates path to IND for PMN310 with GlobeNewswire Inc

May 19, 2021

06:30AM EDT ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics selectively targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced the appointment of Neil Warma, MBA, to its Board of Directors with immediate effect. GlobeNewswire Inc

May 14, 2021

07:00AM EDT ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (ProMIS or the Company), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced its operational and financial results for the three months ended March 31, 2021. GlobeNewswire Inc

May 12, 2021

06:30AM EDT ProMIS Neurosciences appoints renowned neuroscientist, Dr. Rudolph GlobeNewswire Inc

Mar 31, 2021

07:30AM EDT ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (ProMIS or the Company), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced its operational and financial results for the year ended December 31, 2020. GlobeNewswire Inc

Mar 22, 2021

10:45AM EDT ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, is pleased to announce today the completion of an US$7M (CDN$8.75M) private placement of convertible unsecured debentures (the "Debentures"). GlobeNewswire Inc

Feb 2, 2021

08:30AM EST Two positive events in January support PMN310 best in class positioning GlobeNewswire Inc

Jan 12, 2021

06:30AM EST ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, announced today an outline of its strategic priorities and action plan for 2021. GlobeNewswire Inc

Nov 11, 2020

06:30AM EST ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (ProMIS or the Company), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced its operational and financial results for the three and nine months ended September 30, 2020. GlobeNewswire Inc

Nov 9, 2020

06:30AM EST ProMIS Neurosciences offers comments on recent FDA Advisory GlobeNewswire Inc

Oct 30, 2020

06:30AM EDT ProMIS Neurosciences Dr. Neil Cashman CSO, to GlobeNewswire Inc

Oct 29, 2020

06:30AM EDT ProMIS Neurosciences adds Dr. David Wishart to its Scientific GlobeNewswire Inc

Oct 21, 2020

06:30AM EDT ProMIS Neurosciences Offers its Perspective on the Likelihood of GlobeNewswire Inc

Oct 13, 2020

06:30AM EDT ProMIS proprietary drug discovery and development platform highlighted forability to create novel antibodies, diagnostics and vaccine candidates for neurodegenerative diseases GlobeNewswire Inc

Sep 22, 2020

06:30AM EDT ProMIS Neurosciences to develop multivalent vaccine for GlobeNewswire Inc

Aug 13, 2020

06:30AM EDT ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (ProMIS or the Company), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced its operational and financial results for the three and six months ended June 30, 2020. GlobeNewswire Inc

Jul 29, 2020

01:18PM EDT ProMIS Neurosciences Announces Results of Annual Meeting of GlobeNewswire Inc

Share